Literature DB >> 17623119

[Psoriasis und Psoriasis arthritis in childhood and adolescence. Overview and consensus statement of the 9th Wörlitz Expert Round Table Discussion 2006 for the Society for Child and Adolescent Rheumatology].

M Sticherling1, K Minden, R-M Küster, A Krause, M Borte.   

Abstract

There are about 1.2-1.6 million psoriasis sufferers in Germany. In about a third of these, the disease manifests before the age of 20. A classic complication of psoriasis is psoriasis arthritis (PsA), which, from the latest figures, effects about 20% of all psoriasis patients. PsA also starts in childhood and is included under the term juvenile idiopathic arthritis (JIA). The expert round table discussion which took place in 2006 in Wörlitz elaborated the recommendations for the classification, comprehensive diagnostics and therapy of effected children and adolescents. As controlled studies are lacking, the treatment of PsA has been empirically based and carried out in analogy with the treatment of other forms of JIA. The use of methotrexate (MTX) shows a good success rate. In 2004, about a third of the patients found in the core documentation, including over 80% of children and adolescents undergoing a primary therapy, were treated with MTX, a quarter in combination with other medication. A total of 7% of all and 16% of those undergoing primary therapy were treated with etanercept, most (>80%) in combination with basis medication, usually MTX. Consensus opinion indicated that an early, and intensive local skin therapy should be applied in order to reduce inflammatory activity. If PsA is present, the early use of non-steroid anti-inflammatories as well as local therapy of the joints with the intra-articular application of glucocorticosteroids is recommended. The primary medication should preferentially be MTX, if necessary combined with other therapies. In cases of a severe, episodic progression as well as high inflammatory activity, systemic glucocorticosteroids should be considered. Further studies addressing both the clinical course of jPsA compared to the adult manifestation as well as optimal therapeutic procedures should be initiated in the near future.

Entities:  

Mesh:

Year:  2007        PMID: 17623119     DOI: 10.1007/s00393-007-0145-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

1.  [Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee].

Authors:  G Horneff; J Forster; H W Seyberth; H Michels
Journal:  Z Rheumatol       Date:  2000-12       Impact factor: 1.372

Review 2.  Epidemiology of psoriatic arthritis.

Authors:  William J Taylor
Journal:  Curr Opin Rheumatol       Date:  2002-03       Impact factor: 5.006

3.  Prevalence and treatment of psoriasis in the United Kingdom: a population-based study.

Authors:  Joel M Gelfand; Rachel Weinstein; Steven B Porter; Andrea L Neimann; Jesse A Berlin; David J Margolis
Journal:  Arch Dermatol       Date:  2005-12

4.  [Epidemiology of uveitis in juvenile idiopathic arthritis from a national paediatric rheumatologic and ophthalmologic database].

Authors:  A Heiligenhaus; M Niewerth; A Mingels; G Ganser; A Thon; U Pleyer; K Greiner; K Minden
Journal:  Klin Monbl Augenheilkd       Date:  2005-12       Impact factor: 0.700

Review 5.  Clinical and economic burden of psoriasis.

Authors:  Elisabeth Hazard; Spencer B Cherry; Deepa Lalla; J Michael Woolley; Helen Wilfehrt; Chiun-Fang Chiou
Journal:  Manag Care Interface       Date:  2006-04

6.  The natural history of psoriasis in 5,600 patients.

Authors:  E M Farber; M L Nall
Journal:  Dermatologica       Date:  1974

Review 7.  Childhood psoriasis.

Authors:  E M Farber; L Nall
Journal:  Cutis       Date:  1999-11

Review 8.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.

Authors:  Mike J Peters; Irene E van der Horst-Bruinsma; Ben A Dijkmans; Michael T Nurmohamed
Journal:  Semin Arthritis Rheum       Date:  2004-12       Impact factor: 5.532

9.  Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions.

Authors:  K Y Fong; M L Boey; W H Koh; P H Feng
Journal:  Clin Exp Rheumatol       Date:  1994 Jan-Feb       Impact factor: 4.473

10.  Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria.

Authors:  D M Roberton; D A Cabral; P N Malleson; R E Petty
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

View more
  3 in total

Review 1.  [Children and adolescents with psoriasis. What therapy is recommended?].

Authors:  M Sticherling
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

2.  Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.

Authors:  D Windschall; T Müller; I Becker; G Horneff
Journal:  Clin Rheumatol       Date:  2014-07-18       Impact factor: 2.980

Review 3.  Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities.

Authors:  I M G J Bronckers; A S Paller; M J van Geel; P C M van de Kerkhof; M M B Seyger
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.022

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.